Ken Griffin Arcturus Therapeutics Holdings Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$18.08 - $25.38 $133,792 - $187,812	-7,400 Reduced 17.13%	35,800 $830,000
Q2 2024 Aug 14, 2024	BUY	$24.35 - $44.39 $535,700 - $976,580	22,000 Added 103.77%	43,200 $1.05 Million
Q1 2024 May 15, 2024	SELL	$31.23 - $42.99 $477,819 - $657,747	-15,300 Reduced 41.92%	21,200 $715,000
Q4 2023 Feb 14, 2024	SELL	$17.71 - $32.97 $76,153 - $141,771	-4,300 Reduced 10.54%	36,500 $1.15 Million
Q3 2023 Nov 14, 2023	BUY	$25.44 - $37.35 $35,616 - $52,290	1,400 Added 3.55%	40,800 $1.04 Million
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $50,274 - $67,956	2,100 Added 5.63%	39,400 $1.13 Million
Q1 2023 May 15, 2023	SELL	$14.72 - $23.97 $1.42 Million - $2.31 Million	-96,400 Reduced 72.1%	37,300 $894,000
Q4 2022 Feb 14, 2023	BUY	$14.14 - $23.06 $432,684 - $705,636	30,600 Added 29.68%	133,700 $2.27 Million
Q3 2022 Nov 14, 2022	BUY	$13.05 - $22.13 $177,480 - $300,968	13,600 Added 15.2%	103,100 $1.53 Million

179

25.6M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $411M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.